ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
ParticipantActivity from announced rounds
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
Standardizes Korean factory data to connect manufacturers with global defense and industrial buyers
Generates simulation-ready 3D data for physical AI training